TY  - JOUR
A1  - Rabasco Meneghetti, Asier
A1  - Zwanenburg, Alex
A1  - Leger, Stefan
A1  - Leger, Karoline
A1  - Troost, Esther Gera Cornelia
A1  - Linge, Annett
A1  - Lohaus, Fabian
A1  - Schreiber, Andreas
A1  - Kalinauskaite, Goda
A1  - Tinhofer, Inge
A1  - Guberina, Nika
A1  - Guberina, Maja
A1  - Balermpas, Panagiotis
A1  - Müller-von der Grün, Jens
A1  - Ganswindt, Ute
A1  - Belka, Claus
A1  - Peeken, Jan Caspar
A1  - Combs, Stephanie E.
A1  - Böke, Simon
A1  - Zips, Daniel
A1  - Krause, Mechthild
A1  - Baumann, Michael
A1  - Löck, Steffen
T1  - Definition and validation of a radiomics signature for loco-regional tumour control in patients with locally advanced head and neck squamous cell carcinoma
T2  - Clinical and translational radiation oncology
N2  - Purpose: To develop and validate a CT-based radiomics signature for the prognosis of loco-regional tumour control (LRC) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated by primary radiochemotherapy (RCTx) based on retrospective data from 6 partner sites of the German Cancer Consortium - Radiation Oncology Group (DKTK-ROG).
Material and methods: Pre-treatment CT images of 318 patients with locally advanced HNSCC were collected. Four-hundred forty-six features were extracted from each primary tumour volume and then filtered through stability analysis and clustering. First, a baseline signature was developed from demographic and tumour-associated clinical parameters. This signature was then supplemented by CT imaging features. A final signature was derived using repeated 3-fold cross-validation on the discovery cohort. Performance in external validation was assessed by the concordance index (C-Index). Furthermore, calibration and patient stratification in groups with low and high risk for loco-regional recurrence were analysed.
Results: For the clinical baseline signature, only the primary tumour volume was selected. The final signature combined the tumour volume with two independent radiomics features. It achieved moderately good discriminatory performance (C-Index [95% confidence interval]: 0.66 [0.55–0.75]) on the validation cohort along with significant patient stratification (p = 0.005) and good calibration.
Conclusion: We identified and validated a clinical-radiomics signature for LRC of locally advanced HNSCC using a multi-centric retrospective dataset. Prospective validation will be performed on the primary cohort of the HNprädBio trial of the DKTK-ROG once follow-up is completed.
KW  - HNSCC
KW  - Radiomics
KW  - Validation
KW  - Biomarker
KW  - Machine learning
KW  - Loco-regional control
Y1  - 2020
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/57490
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-574908
SN  - 2405-6308
VL  - 26.2021
SP  - 62
EP  - 70
PB  - Elsevier
CY  - Amsterdam [u.a.]
ER  -